Revolutionized Cryopreserved Tumor Infiltrating Lymphocyte Revitalization

A next-generation approach to revitalizing cryopreserved tumor infiltrating lymphocytes, incorporating advanced restimulation protocols, novel cytokine cocktails, and dynamically controlled bioreactors to enhance efficacy and scalability in adoptive cell therapy.

The original patent, 'Restimulation of cryopreserved tumor infiltrating lymphocytes', demonstrated the potential of adoptive transfer of TILs in treating bulky, refractory cancers. However, the current approach has limitations in terms of TIL expansion, cryopreservation, and infusion. The new inventive concept addresses these limitations by introducing a paradigm shift in TIL revitalization, enabling more efficient, scalable, and effective treatment options.

The inventive concept comprises a system for revitalizing cryopreserved TILs, incorporating an aerobic-to-anaerobic metabolic shift inducer, novel cytokine cocktails, and dynamically controlled bioreactors. The method involves cryopreserving TILs, thawing and restimulating them with the cytokine cocktail, and expanding the restimulated lymphocytes in the bioreactor. The device features a chamber for culturing the lymphocytes, a microfluidic system for delivering the restimulation protocol, and a sensor for monitoring the metabolic state of the lymphocytes. The composition for adoptive cell therapy includes the expanded TILs and a cryopreservative solution containing a metabolic modulator, enhancing the in vivo longevity of the lymphocytes. The computer-implemented method optimizes restimulation protocols based on lymphocyte characteristics and predictive modeling.

The new claims introduce a novel cytokine cocktail, aerobic-to-anaerobic metabolic shift inducer, and dynamically controlled bioreactors, which are not obvious from the original patent. The inventive concept's emphasis on metabolic modulation, sensor-enabled monitoring, and predictive modeling-based optimization represents a significant departure from the current state of the art.

Alternative embodiments may include variations in the cytokine cocktail composition, bioreactor design, and sensor types. Additionally, the inventive concept could be adapted for use with other types of immune cells or in combination with other cancer therapies.

The revolutionary TIL revitalization approach has significant commercial potential in the adoptive cell therapy market, targeting patients with bulky, refractory cancers. The inventive concept's scalability and efficacy enhancements position it for widespread adoption in cancer treatment centers and biotech companies.